$1.76 Million in Sales Expected for Miragen Therapeutics Inc (NASDAQ:MGEN) This Quarter

Share on StockTwits

Wall Street brokerages predict that Miragen Therapeutics Inc (NASDAQ:MGEN) will report $1.76 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Miragen Therapeutics’ earnings. The lowest sales estimate is $1.00 million and the highest is $2.51 million. Miragen Therapeutics posted sales of $940,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 87.2%. The business is scheduled to report its next earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that Miragen Therapeutics will report full year sales of $5.08 million for the current fiscal year, with estimates ranging from $2.90 million to $7.91 million. For the next fiscal year, analysts anticipate that the business will report sales of $5.53 million, with estimates ranging from $1.00 million to $10.06 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Miragen Therapeutics.

Miragen Therapeutics (NASDAQ:MGEN) last announced its earnings results on Wednesday, August 7th. The medical research company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.08. The business had revenue of $2.51 million during the quarter, compared to the consensus estimate of $0.89 million. Miragen Therapeutics had a negative net margin of 925.52% and a negative return on equity of 78.14%.

A number of analysts have issued reports on MGEN shares. ValuEngine raised shares of Miragen Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research raised shares of Miragen Therapeutics from a “hold” rating to a “strong-buy” rating and set a $1.25 price objective for the company in a report on Tuesday. Finally, Wedbush reissued a “buy” rating and issued a $24.00 price objective on shares of Miragen Therapeutics in a report on Tuesday, May 21st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $15.69.

NASDAQ MGEN traded down $0.01 during trading on Thursday, reaching $0.83. The company’s stock had a trading volume of 182,639 shares, compared to its average volume of 196,315. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $38.19 million, a price-to-earnings ratio of -0.76 and a beta of 1.12. Miragen Therapeutics has a 12 month low of $0.78 and a 12 month high of $6.43. The firm has a 50 day moving average price of $1.93 and a 200 day moving average price of $2.55.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in shares of Miragen Therapeutics during the 2nd quarter valued at approximately $159,000. Citadel Advisors LLC acquired a new position in Miragen Therapeutics during the second quarter worth $57,000. Paloma Partners Management Co acquired a new position in Miragen Therapeutics during the second quarter worth $239,000. Invesco Ltd. acquired a new position in Miragen Therapeutics during the second quarter worth $71,000. Finally, Vanguard Group Inc. boosted its stake in Miragen Therapeutics by 37.7% during the second quarter. Vanguard Group Inc. now owns 617,914 shares of the medical research company’s stock worth $1,267,000 after buying an additional 169,086 shares during the last quarter. 42.68% of the stock is owned by hedge funds and other institutional investors.

Miragen Therapeutics Company Profile

Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.

Recommended Story: What is a Swap?

Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.